ArticleAllergy2019
Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses.
Article in Allergy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 61 citations in OpenAlex.
- Validation of an improved insect bite hypersensitivity severity score for allergic equine insect bite hypersensitivity in horses.Journal of veterinary internal medicine · 2026Article
- Article
- Taming pet allergens: strategies to make furry cats less allergenic.Frontiers in allergy · 2026Review
- Article
- Vaccine-Induced Anti-IgE Antibodies Neutralize Free IgE but Fail to Bind and Activate Mast Cell-Displayed IgE.Allergy · 2025Article
- Phenotypic Shift of an Inflammatory Eosinophil Subset into a Steady-State Resident Phenotype after 2 Years of Vaccination against IL-5 in Equine Insect Bite Hypersensitivity.Veterinary sciences · 2024Article
- Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments.International journal of molecular sciences · 2024Review
- Article
- Article
- Preclinical Evaluation of virus-like particle Vaccine Against Carbonic Anhydrase IX Efficacy in a Mouse Breast Cancer Model System.Molecular biotechnology · 2024Article
- Cytokines and chemokines skin gene expression in correlation with immune cells in blood and severity in equine insect bite hypersensitivity.Frontiers in immunology · 2024Article
- Insect Bite Hypersensitivity in Horses: Causes, Diagnosis, Scoring and New Therapies.Animals : an open access journal from MDPI · 2023Review
- Development of an inhibiting antibody against equine interleukin 5 to treat insect bite hypersensitivity of horses.Scientific reports · 2023Article
- In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma.Journal for immunotherapy of cancer · 2022Article
- Virus-like particle vaccinology, from bench to bedside.Cellular & molecular immunology · 2022Review
- Atopic Dermatitis in Domestic Animals: What Our Current Understanding Is and How This Applies to Clinical Practice.Veterinary sciences · 2021Review
- Bioengineering of Virus-like Particles for the Prevention or Treatment of Allergic Diseases.Allergy, asthma & immunology research · 2021Review
- Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy.Annual review of virology · 2020Review
- The 3Ds in virus-like particle based-vaccines: "Design, Delivery and Dynamics".Immunological reviews · 2020Review
- Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses.Vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundInsect-bite hypersensitivity (IBH) in horses is a chronic allergic dermatitis caused by insect bites. Horses suffer from pruritic skin lesions, caused by type-I/type-IV allergic reactions accompanied by prominent eosinophil infiltration into the skin. Interleukin-5 (IL-5) is the key cytokine for eosinophils and we have previously shown that targeting IL-5 by vaccination reduces disease symptoms in horses.
objectiveHere, we analyzed the potential for long-term therapy by assessing a second follow-up year of the previously published study.
methodsThe vaccine consisted of equine IL-5 (eIL-5) covalently linked to a cucumber mosaic virus-like particle (VLP) containing a universal T cell epitope (CuMV
resultsThe vaccine was well tolerated and did not reveal any safety concerns throughout the study. Upon vaccination, all horses developed reversible anti-eIL-5 auto-antibody titers. The mean course of eosinophil levels was reduced compared to placebo treatment leading to significant reduction of clinical lesion scores. Horses in their second vaccination year showed a more pronounced improvement of disease symptoms when compared to first treatment year, most likely due to more stable antibody titers induced by a single booster injection. Hence, responses could be maintained over two seasons and the horses remained protected against disease symptoms.
conclusionYearly vaccination against IL-5 may be a long-term solution for the treatment of IBH and other eosinophil-mediated diseases in horses and other species including humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.